Last reviewed · How we verify
urothelial carcinoma uc
Approved treatments
Clinical guidelines
- FDA label — adjuvant
Adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. - FDA label — 1L
Adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. - FDA label — 2L
Adult patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- urothelial carcinoma uc patent landscape — cliff calendar, originator estates, attackable patents
- urothelial carcinoma uc treatment landscape brief
- urothelial carcinoma uc treatment updates RSS
Frequently asked questions about urothelial carcinoma uc
What are the treatment guidelines for urothelial carcinoma uc?
FDA label publishes guidelines for urothelial carcinoma uc. 3 guideline references tracked.
Related
- Treatment landscape: urothelial carcinoma uc patent cliff · urothelial carcinoma uc CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing